Esperion Therapeutics, Inc. (ESPR)
NASDAQ: ESPR · Real-Time Price · USD
1.820
-0.030 (-1.62%)
At close: Feb 21, 2025, 4:00 PM
1.840
+0.020 (1.10%)
After-hours: Feb 21, 2025, 7:59 PM EST
Esperion Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Esperion Therapeutics stock have an average target of 7.25, with a low estimate of 2.50 and a high estimate of 16. The average target predicts an increase of 298.35% from the current stock price of 1.82.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Esperion Therapeutics stock from 6 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 1 | 2 | 2 |
| Hold | 1 | 1 | 0 | 1 | 1 | 1 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 3 | 5 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $16 | Strong Buy | Reiterates | $16 | +779.12% | Feb 11, 2025 |
| JMP Securities | JMP Securities | Buy Reiterates $7 | Buy | Reiterates | $7 | +284.62% | Jan 23, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $16 | Strong Buy | Reiterates | $16 | +779.12% | Jan 23, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates n/a | Strong Buy | Reiterates | n/a | n/a | Jan 10, 2025 |
| Goldman Sachs | Goldman Sachs | Hold Initiates $4 | Hold | Initiates | $4 | +119.78% | Dec 18, 2024 |
Financial Forecast
Revenue This Year
333.72M
from 116.33M
Increased by 186.86%
Revenue Next Year
365.13M
from 333.72M
Increased by 9.41%
EPS This Year
-0.32
from -2.03
EPS Next Year
-0.04
from -0.32
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 359.1M | 420.5M | 451.5M | |||
| Avg | 333.7M | 365.1M | 384.1M | |||
| Low | 308.1M | 274.2M | 326.2M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 208.7% | 26.0% | 23.7% | |||
| Avg | 186.9% | 9.4% | 5.2% | |||
| Low | 164.8% | -17.8% | -10.7% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.26 | 0.32 | 0.21 | ||
| Avg | -0.32 | -0.04 | 0.03 | ||
| Low | -0.36 | -0.60 | -0.32 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.